As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Meanwhile, other companies are also targeting ATTR-CM, including Alnylam ... Both these are already approved to treat ATTR-PN, as Amvuttra and Wainua, respectively. BridgeBio is pointing to ...

Vutrisiran is already approved as Amvuttra to treat polyneuropathy caused ... and recurrent cardiovascular events in its phase 3 ATTRibute-CM trial and could be approved by the FDA in November.

This approval expands the indication for Amvuttra, making it the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated ...

The study included 8 patients with ATTR-CM (average age, 62.8 years), divided into 2 cohorts ... 6 patients received patisiran (Onpattro ®), and the remaining 2 received vutrisiran (Amvuttra ®). These ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...